65,437 trials
Anemia
Primary: Number of Subjects Who Achieved 'Success' Meaning a ≥ 2.0 Increase in Hemoglobin — 162; 159 participants
Pancreatic Cancer
Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants
Acute Otitis Externa
Primary: Adverse Events (AEs) — 10; 3; 6; 1 participants
Colorectal Cancer
Primary: Increase (Percent) of Polyps Detected That Would Have Been Missed Without the Third Eye Retroscope (TER) — 13.2 percent of polyps
Multiple Myeloma
Primary: Best Overall Response Rate (ORR) — 16.7; 23.7 % of participants w/ PR or better
Hepatitis C, Chronic
Primary: The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12) — 88.6; 61.7…
Heart Failure
Primary: Responder Rate — 67; 60 percentage of participants
Healthy
Primary: Area Under Curve From 0 to Infinity Hours (AUC0-∞) — 912; 610 ng*h/mL
Atopic Dermatitis
Primary: Change From Baseline in Three Item Severity Score — -2.6; -3.6 units on a scale
Duchenne Muscular Dystrophy
Primary: Number of Subjects With an Adverse Event. — 1; 0; 0; 0 participants
Myelodysplastic Syndrome
Primary: Phase II: Overall Remission Rate (ORR): Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR) - as Per International Working Group (IWG)…
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete Response — 437; 238 Participants
Sprain of Ankle
Primary: Patient's Assessment of Ankle Pain (VAS)- Absolute Value Decrease on Day 7 — -33.00; -37.10; -37.10 Absolute value units on a scale VAS
Attention Deficit Hyperactivity Disorder
Primary: Adult ADHD Investigator Symptom Rating Scale (AISRS) — 37.0; 15.0 units on a scale
Primary Biliary Cirrhosis
Primary: Change in Serum Alkaline Phosphatase Levels. — -57.3 U/L — p=0.001